Among the many things columnist Candace Semien had to learn while living with lupus were the types and function of various ...

The focus of this year’s awareness month is “Make Lupus Visible” — given that the chronic condition is often invisible to others. For World Lupus Day on May 10, the World Lupus Federation, a global ...

The FDA’s decision to grant the designation to FT819 was based in part on early data from an ongoing Phase 1 clinical trial (NCT06308978) that’s testing the therapy in people with systemic lupus ...

Developed by Roche’s subsidiary Genentech and Biogen, obinutuzumab is an antibody-based treatment, already approved for certain blood cancers, that was found in a clinical trial to ease symptoms of ...

If my body contributed to the Job of Living, it was limited to completing and surviving the day’s tasks and soaking in only essential oils and hot water. While I strategically planned to execute the ...

Fast track status for SLE follows similar designation last year for lupus nephritis To treat SLE, Adicet Bio is advancing ADI-001, its lead product candidate and a first-in-class CAR T cell therapy, ...

Both prayers are reverent requests to receive strength and people that will help heal the body, mind, and soul. And, yes, both prayers stated what I needed when I didn’t have the cognitive or ...

Fast track status is given to therapies that have the potential to improve care for serious diseases, with the goal of speeding the review and development of possibly important new treatments. The FDA ...

The isolated T-cells are sent to a lab, where they are genetically engineered to be equipped with a chimeric antigen receptor (CAR) that recognizes a specific target of interest. In the case of CAR ...

The Phase 1 study will enroll people with moderate to severe SLE who’ve failed to respond to at least two standard immunosuppressive medications. Century expects the trial will start in the first half ...

Brepocitinib designed to block action of TYK2 and JAK1 enzymes Brepocitinib is a first-in-class oral medication designed to block the action of two enzymes — TYK2 and JAK1 — that are involved in ...

Specifically, 78% of lupus patients with cardiovascular risk factors reported clinically relevant anxiety, and 93% had depression. In contrast, prior studies in SLE patients without such risk factors ...